Terns Pharmaceuticals (TERN) Projected to Post Earnings on Monday

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.03. On average, analysts expect Terns Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Terns Pharmaceuticals Price Performance

Shares of NASDAQ TERN traded up $0.04 during trading hours on Friday, reaching $3.04. The stock had a trading volume of 902,991 shares, compared to its average volume of 1,531,902. Terns Pharmaceuticals has a twelve month low of $1.87 and a twelve month high of $11.40. The business's fifty day moving average is $2.90 and its two-hundred day moving average is $4.61. The company has a market cap of $265.50 million, a price-to-earnings ratio of -2.58 and a beta of -0.16.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. William Blair reiterated a "market perform" rating on shares of Terns Pharmaceuticals in a research report on Friday, March 21st. JMP Securities reaffirmed a "market outperform" rating and set a $20.00 price objective on shares of Terns Pharmaceuticals in a report on Monday, April 21st. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $18.38.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.